Armlogi gets Nasdaq approval to transfer to Capital Market; 180-day bid price cure extension

Armlogi Holding Corp.

Transfer from Nasdaq Global Market to Capital Market approved, effective May 8, 2026.
Second compliance period until November 2, 2026 to regain $1.00 minimum bid price.
Automatic cure of prior MVPHS deficiency (market value of publicly held shares < $5M).
Company may consider reverse stock split if needed to meet bid price requirement.
Failure to cure by deadline could result in delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.